Seizure

World Champion and Olympic Medalist Marion Clignet, Technological Co-Founder of Jelenew Launches "Sprinters Jersey Lab"

Retrieved on: 
Wednesday, February 21, 2024

WILMINGTON, Del., Feb. 21, 2024 /PRNewswire/ -- "When I was 22, I woke up on the floor of a store, surrounded by people asking me my name and where I lived. I knew the answers, but I couldn't tell them." This seizure and the following diagnosis of epilepsy cost Marion Clignet her driver's license, and she started commuting by bicycle. Thus began the champion's journey of an epilepsy patient. Since 1990, she has placed first in six world championship and won two silver medals at the Olympics representing France. She also broke the world record at the time in 1996 and won the French national championship many times including individual pursuit and road races.  projects.  She achieved more than 350 victories in her career, including stage wins and winning jerseys in the women's Tour de France and the Giro Women's Tour.

Key Points: 
  • Since 1990, she has placed first in six world championship and won two silver medals at the Olympics representing France.
  • She also broke the world record at the time in 1996 and won the French national championship many times including individual pursuit and road races.
  • She competed against men in Brittany multiple times, winning many supporters and bringing more public attention to women's cycling.
  • This project is her new journey to accomplish her mission to empower women cyclists around the world.

The Angelman Syndrome Foundation (ASF) and Cedars-Sinai Guerin Children's team up to launch new clinic for families living with Angelman syndrome

Retrieved on: 
Tuesday, February 20, 2024

AURORA, Ill., Feb. 20, 2024 /PRNewswire-PRWeb/ -- The Angelman Syndrome Foundation is proud to announce a new collaboration with Cedars-Sinai Guerin Children's to launch a new clinic for patients with Angelman syndrome, a rare neuro-genetic disorder.

Key Points: 
  • The Angelman Syndrome Foundation is proud to announce a new collaboration with Cedars-Sinai Guerin Children's to launch a new clinic for patients with Angelman syndrome, a rare neuro-genetic disorder.
  • AURORA, Ill., Feb. 20, 2024 /PRNewswire-PRWeb/ -- The Angelman Syndrome Foundation is proud to announce a new collaboration with Cedars-Sinai Guerin Children's to launch a new clinic for patients with Angelman syndrome, a rare neuro-genetic disorder.
  • The clinic is led by Cesar Ochoa-Lubinoff, MD, MPH , director of Developmental-Behavioral Pediatrics at Cedars-Sinai Guerin Children's, who previously co-directed the Angelman syndrome clinic at Rush University Medical Center in Chicago.
  • "In my experience, families facing Angelman syndrome are resilient, but they need a supportive medical team in place," Ochoa-Lubinoff said.

The Inner Circle Acknowledges, Jose A. Matus as a Top Pinnacle Professional

Retrieved on: 
Monday, February 19, 2024

SHERMAN, Texas, Feb. 19, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Jose A. Matus is acknowledged as a Top Pinnacle Professional for his contributions to the field of neurology.

Key Points: 
  • SHERMAN, Texas, Feb. 19, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Jose A. Matus is acknowledged as a Top Pinnacle Professional for his contributions to the field of neurology.
  • Dr. Matus earned a medical degree from the School of Medicine at The Universidad de San Carlos de Guatemala in 1982.
  • He finished a Neurology Residency in 1995 at the Loma Linda University Medical Center in Loma Linda, CA.
  • Dr. Matus sees patients for acute neurology care and performs neuro-diagnostic procedures like EMG, NCV EEGs, and Carotid Ultrasounds.

NCLA Amicus Brief Exposes Fatal Constitutional Flaws in SEC’s Illegal Mass Data Collection Regime

Retrieved on: 
Thursday, February 15, 2024

SEC’s CAT is an unprecedented mass confiscation of personal financial data in blatant violation of the Fourth Amendment’s restrictions on unreasonable searches and seizures.

Key Points: 
  • SEC’s CAT is an unprecedented mass confiscation of personal financial data in blatant violation of the Fourth Amendment’s restrictions on unreasonable searches and seizures.
  • No law passed by Congress gives SEC authority to set up a data collection and surveillance system.
  • NCLA released the following statements:
    “The CAT is an illegal SEC power grab that violates ordinary Americans’ basic constitutional rights.
  • This Leviathan-sized dragnet is absurd, risky, and utterly unlawful.”
    — Mark Chenoweth, President and Chief Legal Officer, NCLA

Spice: the ‘zombie drug’ being found in some vape liquids

Retrieved on: 
Thursday, February 15, 2024

This incident is only the latest in what appears to be a growing problem in the UK with unregulated vape liquids, especially those marketed as containing THC or cannabis.

Key Points: 
  • This incident is only the latest in what appears to be a growing problem in the UK with unregulated vape liquids, especially those marketed as containing THC or cannabis.
  • This is why it’s so important for users to think carefully about what vape products they use.

What is spice?

  • While these lab-made drugs are designed to mimic the effects of cannabis, they tend to be far more unpredictable and harmful.
  • There’s currently no data on how these drugs are manufactured in clandestine laboratories thought to be located in China and India.
  • But we do have some idea of how spice may be synthesised, based on academic experiments that have been published in peer-reviewed journals.

What makes spice harmful?

  • Studies have shown that the compounds contained in spice act on both types of cannabinoid receptors that the body has.
  • Those who use spice repeatedly can develop a tolerance to it, requiring more to achieve the desired effect – ultimately putting them at higher risk of harm.

How does spice affect users?


Synthetic cannabinoid receptor agonists were initially explored as experimental drugs to alleviate suffering related to a variety of conditions – including pain, anorexia, muscle spasms and glaucoma.

  • Many people use spice in the hopes of experiencing effects similar to those caused by cannabis.
  • It isn’t possible to predict who will suffer which of these side effects, but all spice users are at risk.

Is spice a growing problem?

  • One investigation even found that nearly half of male prison deaths that happened between 2015-2020 in England and Wales were due to Spice.
  • There is also an increasing number of reports in the press of vape liquids being laced with spice – leading public health authorities to issue warnings.
  • There are now calls to make young people more aware of the dangers of spice and using certain types of vape liquids.


Michael Cole receives funding and "in kind" support from the European Union and a number police forces and forensic science organisations around the world to carry out research.

Recognizing when someone is having a seizure – and how you can help during those first critical moments

Retrieved on: 
Wednesday, February 14, 2024

But experiencing a seizure does not always mean a person has epilepsy.

Key Points: 
  • But experiencing a seizure does not always mean a person has epilepsy.
  • Seizures can be provoked by acute head injuries, alcohol withdrawal and high blood sugar, among other things.

What does a seizure look like?

  • For some people, their seizure is a purely internal sensation.
  • In fact, most people with epilepsy have only relatively subtle, nonconvulsive seizures at first, then develop convulsive seizures over time.
  • This is the type of seizure most of us are familiar with, probably because it’s the kind most frequently depicted, though not always accurately, in movies and on television.
  • The most common type of epileptic seizure are those that are focal – that is, they arise from a confined region of the brain.

What causes a seizure to occur?


Seizures are the result of abnormal electrical activity in the brain. The bursts of activity disrupt normal functioning and initiate hyperactivity in the affected brain area, which then can affect the corresponding body part. For instance, if the seizure arises from the part of the brain involved in arm movement, that arm will experience involuntary hyperactivity.

If you’re a bystander, how can you help?

  • Many seizure-related injuries occur due to falling or coming in contact with sharp or hard objects.
  • If they begin to fall, help them to the floor as gently as possible and put something soft under their head.
  • During the convulsive phase of a seizure, breathing may be intermittent.
  • So turn the person on their side so they can breathe more easily and lower the risk of aspiration.
  • Following the seizure, and as the person gradually recovers and wakes up, help them sit up in a safe space.

Are new treatments available?

  • People with epilepsy, particularly those who experience frequent seizures, will often have emergency medications in their possession.
  • The most common emergency medications – also called seizure rescue medications – are a type of anticonvulsants called benzodiazepines.
  • Patients and their caretakers may have access to rescue medications and know how to use them.

What if it’s not a seizure?


If a bystander does not witness a seizure, but instead finds someone unresponsive or minimally responsive, call 911. They may be suffering from other medical issues, such as a drug overdose. And if you are interested in training and certification for seizure first aid, or if you simply want to know more, the Epilepsy Foundation has more information.

  • Jacob Pellinen has received research support from the Department of Neurology at the University of Colorado School of Medicine, the Colorado Clinical and Translational Sciences Institute, NIH/NINDS, and the American Epilepsy Society.
  • J. Pellinen serves as chair of the professional advisory board for the Epilepsy Foundation of Colorado and Wyoming (unpaid), serves as the Epilepsy Section Editor for Current Neurology and Neuroscience Reports, and has received compensation for serving on the scientific advisory board for SK Life Science.

In a Historic Move Beagle Freedom Project Closes Animal Testing Laboratory in Nowata, Oklahoma and Rescues Over 200 Dogs and Cats from Certain Death

Retrieved on: 
Wednesday, February 14, 2024

Beagle Freedom Project has now taken over the 30-acre Nowata, Oklahoma property and facilities where animals were previously held captive, and is transforming the space into Freedom Fields, a rescue, rehabilitation, and adoption center.

Key Points: 
  • Beagle Freedom Project has now taken over the 30-acre Nowata, Oklahoma property and facilities where animals were previously held captive, and is transforming the space into Freedom Fields, a rescue, rehabilitation, and adoption center.
  • More than 200 dogs and cats have been surrendered from this now closed laboratory, and liberated from a lifetime of toxic and painful testing, and they are safe with BFP.
  • Freedom Fields is where dogs, cats, rabbits and farm animals Beagle Freedom Project rescues from animal testing and experimentation will receive thorough medical care, nutritious food, safe and beautiful habitats, space to roam, and all the protection, love, play, enrichment, and freedom they have been deprived of their entire lives.
  • Rehabilitated animals will be carefully matched to foster and adoptive families by BFP’s dedicated adoption coordination team.

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

Retrieved on: 
Tuesday, February 13, 2024

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2023, and recent updates.

Key Points: 
  • Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2023, and recent updates.
  • Second Quarter Fiscal Year 2024 and Subsequent Highlights:
    “Anebulo continues to make progress towards our goal of becoming the first company to have an approved treatment for acute cannabinoid intoxication.
  • “We are pleased to report that the USAN Council has adopted selonabant as the generic name for ANEB-001.
  • Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 million, or $(0.15) per share, in the second quarter of fiscal 2023.

Avicanna Obtains Its First Indication-Specific Drug Registration with Trunerox™

Retrieved on: 
Tuesday, February 13, 2024

“The approval of our first pharmaceutical product is an exceptionally significant milestone and a major step towards our long-term vision as a biopharmaceutical company with the aim to serve patients with unmet medical needs.

Key Points: 
  • “The approval of our first pharmaceutical product is an exceptionally significant milestone and a major step towards our long-term vision as a biopharmaceutical company with the aim to serve patients with unmet medical needs.
  • It is also rewarding to be able to deliver this medication for such a critical medical condition at an accessible price through our vertical,” stated Aras Azadian, CEO.
  • The approval allows Avicanna to manufacture and commercialize Trunerox in Colombia with approved indications and claims associated to the treatment for seizures related to Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS).
  • Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) are two of the various, rare epileptic disorders classified as epileptic encephalopathies.

Santé's Expert Commentary on the Danger of Tianeptine or "Gas Station Heroin"

Retrieved on: 
Monday, February 12, 2024

ARGYLE, Texas, Feb. 12, 2024 /PRNewswire-PRWeb/ -- The U.S. Food and Drug Administration (FDA) recently issued a new and urgent warning about using any products, such as Neptune's Fix, that contain tianeptine. They sent a letter on January 11, 2024 to convenience stores, gas stations, vape/smoke shops and other companies advising the retailers to stop selling any tianeptine-containing products. In November, they issued an initial warning and have continued to receive reports on the adverse effects of tianeptine, including seizures, loss of consciousness and death.

Key Points: 
  • In November, they issued an initial warning and have continued to receive reports on the adverse effects of tianeptine, including seizures, loss of consciousness and death.
  • There have been reported instances of individuals using tianeptine as an opioid substitute or to self-treat anxiety and depression.
  • In fact, tianeptine products are being touted "with claims to improve brain function and treat anxiety, depression, pain, opioid use disorder and other conditions.

  • "There have been reported instances of individuals using tianeptine as an opioid substitute or to self-treat anxiety and depression.